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VAPB (vesicle-associated membrane 
protein-associated protein B) is a tail-
anchored protein that is present at several 
contact sites of the endoplasmic reticulum 
(ER). We now show by immunoelectron 
microscopy that VAPB also localizes to the 
inner nuclear membrane (INM). Using a 
modified APEX2 (enhanced ascorbate 
peroxidase 2)-approach with rapamycin-
dependent targeting of the peroxidase to a 
protein of interest, we searched for proteins 
that are in close proximity to VAPB, 
particularly at the INM. In combination 
with stable isotope labeling with amino 
acids in cell culture (SILAC), we confirmed 
many well-known interaction partners at 
the level of the ER with a clear distinction 
between specific and non-specific hits. 
Furthermore, we identified emerin, 
TMEM43 and ELYS as potential 
interaction partners of VAPB at the INM 
and the nuclear pore complex, respectively. 
The family of vesicle-associated membrane 
protein (VAMP/synaptobrevin) associated 
proteins (VAPs) includes VAPA and VAPB 
with described roles in the morphology and the 
function of the endoplasmic reticulum (ER) 
and the Golgi apparatus (1,2). VAPB is a tail-
anchored protein, i.e. a protein containing a 
single transmembrane domain close to its C-
terminus. Such proteins are typically inserted 
into the cellular membrane system in a post-
translational manner (3,4). In its N-terminal 
region, VAPB contains a characteristic major 
sperm protein (MSP) domain. VAPB localizes 
largely to the ER and its binding to several 
partner proteins has been shown to mediate the 
association of the ER with other organelles. 
The acyl-CoA binding domain protein 5 
(ACBD5), for example, interacts with VAPB 
and is involved in binding peroxisomes to the 
ER (5), whereas tyrosine phosphatase 
interacting protein 51 (PTPIP51) and VAPB 
form an ER-mitochondria tethering complex 
(6). In the secretory pathway, VAPB interacts 
with the Yip1-interacting factor homologue 
YIF1A, e.g. at the level of the ER-Golgi 
intermediate compartment (7). Furthermore, 
several oxysterol binding proteins (OSBPs), 
which play important roles in lipid transport, 
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interact with VAPB (8) and Kv2 potassium 
channels form ER-plasmamembrane junctions 
via interactions with VAPB (9). In total, >100 
proteins have been reported to directly or 
indirectly interact with VAPB and/or the 
highly similar protein VAPA (10,11) (see also 
https://thebiogrid.org). A major binding motif, 
which is found in many VAPB-interacting 
proteins, is the “two phenylalanines in an 
acidic tract” (FFAT)-motif (11,12). Typically, 
the FFAT- (or FFAT-like) motif interacts with 
the MSP-domain of VAPB. One example for a 
protein containing the FFAT-motif that binds 
VAPB is the WD repeat-containing protein 
WDR44 (13). A mutation in VAPB (P56S) is 
involved in an autosomal dominant form of 
amyotrophic lateral sclerosis (ALS) (14) and 
blocks transport of nucleoporins and emerin, a 
major protein of the inner nuclear membrane 
(INM), to the nuclear envelope (15). 
Several methods have been developed for the 
identification of proteins that are in close 
proximity to each other. They typically 
introduce biotin into unknown proteins as a tag 
that can be used for affinity capture with 
immobilized streptavidin and subsequent 
analysis by mass-spectrometry (for review see 
(16,17)). One prominent approach, proximity-
dependent biotin identification (BioID), is 
based on a mutant form of the biotin ligase 
BirA, which can be fused to a protein of 
interest (the bait) whose neighboring proteins 
are to be analyzed (18). The enzyme part of the 
fusion protein releases reactive biotin, which 
can modify proteins (the prey) within a small 
spatial range. One drawback of this method is 
a rather long reaction time of >15 hours, 
although a faster method has been described 
very recently (19). As an alternative to biotin 
ligase dependent modifications, peroxidase-
based methods have been introduced that allow 
short reaction times in the range of seconds to 
minutes (20). Ascorbate peroxidase (APEX) is 
a plant enzyme that generates biotin-phenoxyl 
radicals from biotin phenol in the presence of 
H2O2. These radicals have a very short half-life 
and, thus, can modify proteins within a range 
of ~20 nm, reacting with several amino acids 
with tyrosine as the primary site of 
biotinylation (21). Importantly, APEX can be 
fused to the N- or the C-terminus of proteins 
and may also reside internally. Furthermore, 
the enzyme has been shown to be active in 
several cellular compartments (20,22,23). 
Recently, APEX2 was introduced, which is far 
more active than the original enzyme (24). So 
far, APEX- or APEX2-based methods have 
mainly been used for the identification of 
proteins that reside in defined subcellular 
compartments, e.g. in primary cilia (23) or in 
the intermembrane space of mitochondria (25). 
As an alternative to APEX, horseradish 
peroxidase (HRP) can also be used as an 
enzyme to initiate the formation of biotin-
phenoxyl radicals, and antibody-directed 
targeting of HRP to proteins of interest was 
recently described (26).  
We previously characterized the post-
translational insertion mechanisms of emerin 
into ER-membranes and analyzed targeting of 
the protein to the INM (27). For this, we 
applied a rapamycin-dependent dimerization 
method to monitor sequestration of a soluble 
nuclear reporter protein (dGFP-GST-NLS-
FKBP12) to mCherry-tagged emerin 
(mCherry-FRB-emerin) at the INM. In this 
system, rapamycin binds to its two cognate 
binding regions, a 12-kDa FK506 binding 
protein (FKBP12) and an FKBP-rapamycin-
binding (FRB)-cassette, promoting rapid 
interaction of the appropriately tagged proteins 
(28).  
We now combine the APEX2-technology with 
the rapamycin-dependent dimerization 
approach. To this end, we target FKBP12-
tagged APEX2 to FRB-tagged proteins in a 
rapamycin-dependent manner. SILAC, 
followed by quantitative mass spectrometry, 
then allows the comparison of proteins that get 
biotinylated by APEX2 in either the absence or 
the presence of rapamycin. Using this method 
(rapamycin- and APEX-dependent 
identification of proteins by SILAC or 
RAPIDS), we found RMDN3 (PTPIP51), 
ACBD5, YIF1A, OSBPL9 and other 
previously known interacting proteins of 
VAPB. Using a version of APEX2 that 
accumulates in the nucleus, we identified 
additional neighboring proteins of VAPB that 
reside at the nuclear envelope, e.g. emerin, 
TMEM43, lamins and the nucleoporin ELYS 
(embryonic large molecule derived from yolk 
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sac; AHCTF1). We further demonstrate the 
INM-localization of VAPB by 
immunoelectron microscopy and confirm the 
close proximity of endogenous VAPB with 
several of the newly identified proteins using 





VAPB resides at the INM 
VAPB is typically described as an ER-resident 
protein, mediating interactions with multiple 
organelles. In addition, VAPB seems to play a 
role in the dynamics of the nuclear envelope 
and the nuclear pore complex. In this context, 
it was reported to affect transport of emerin to 
the INM (15). A localization of VAPB itself to 
the INM, however, has not been demonstrated 
so far. We therefore investigated the 
subcellular localization of VAPB in detail. 
First, we analyzed endogenous VAPB by 
indirect immunofluorescence using different 
buffers for the procedure. The specificity of 
the anti-VAPB antibody was confirmed by 
siRNA-mediated knockdown (compare Fig. 6). 
As shown before, VAPB localized to the 
endoplasmic reticulum (ER), with a clear rim 
around the nucleus visible in many cells (Fig. 
1A). Interestingly, the ratio of the ER- and the 
nuclear envelope signal varied a lot, depending 
on the buffer used (compare (i) and (ii)). 
Similar to the endogenous protein, differently 
tagged versions of VAPB (mCherry-FRB-
VAPB and HA-FRB-VAPB) were also found 
at the level of the ER and the nuclear envelope 
(Fig. 1B). We next tested if the nuclear rim 
could reflect targeting of VAPB not only to the 
outer, but also to the inner nuclear membrane. 
For readout, we used our established 
rapamycin-system (27). As shown before for 
emerin, the nuclear reporter protein dGFP-
GST-NLS-FKBP12 was sequestered to the 
nuclear rim upon the addition of rapamycin in 
cells co-expressing mCherry-FRB-VAPB (Fig. 
1C). This result suggested that at least a 
portion of the exogenously expressed VAPB 
reached the INM. To unequivocally 
demonstrate INM-localization of endogenous 
VAPB, we performed immunoelectron 
microscopy. As shown in Fig. 1D, 
immunoreactivity was detected at 
mitochondria, possibly reflecting the 
interaction of VAPB with PTPIP51. 
Furthermore, a significant number of gold dots 
were found at the level of the INM and also in 
close proximity to nuclear pores. In addition to 
these morphological studies, we also 
performed biochemical analyses. Obtaining 
pure INM-fractions is hardly possible, 
nevertheless, we subjected cell lysates to an 
established fractionation protocol (29). As 
shown in Fig. S1, VAPB was largely recovered 
in the same fraction as emerin and other 
proteins of the nuclear envelope, although 
other membrane proteins are certainly 
expected in this fraction as well. Together, our 
results clearly point to a localization of a 
fraction of the cellular VAPB-pool at the INM. 
They are in line with a recent study that was 
published during the review process of this 
paper, suggesting a role of VAPB in nuclear 
egress of Herpes Simplex viral particles (30). 
 
APEX2-dependent biotinylation of proteins 
A number of membrane proteins exposing 
binding regions to the cytoplasm have been 
shown to interact with the ER-form of VAPB 
(2). A portion of VAPB, however, localizes to 
the INM and we now set out to devise a 
method for the identification of neighboring 
partners of VAPB that allows to focus on 
either the cytoplasm (where the majority of 
VAPB is expected) or the nuclear 
compartment. Our approach is based on the 
APEX2-method for identification of proximity 
partners. In a “classic” approach, we first fused 
APEX2 directly to VAPB (Fig. 2A, left), as 
done before for many other proteins (9,20-
23,25,31-35). HeLa cells were transfected with 
constructs coding for APEX2-VAPB or, for a 
control reaction, GFP-APEX2. Fig. 2B shows 
the subcellular localization of the APEX2-
fusion proteins: as expected, GFP-APEX2 is 
found all over the cell and should promote 
unspecific biotinylation of many cellular 
proteins, whereas APEX2-VAPB localizes 
largely to the ER, very similar to other fusion 
proteins of VAPB (compare Fig. 1B). Next, 
the cells were subjected to the biotinylation 
protocol, including loading of cells with biotin-
phenol and a short pulse with H2O2. For 
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analysis, biotinylated proteins were enriched 
using neutravidin beads and detected by 
Western-blotting. As shown in Fig. 2C, both 
fusion proteins were detected at similar levels 
in total cell lysates and in the protein fractions 
as bound to the neutravidin beads, indicating 
self-biotinylation. Furthermore, they led to a 
similar pattern of biotinylated proteins as 
detected by streptavidin-HRP. Next, we probed 
the blots with antibodies against proteins that 
had previously been identified as interaction 
partners of VAPB. Indeed, ACBD5 and 
OSBPL9 were clearly enriched when cells 
expressed APEX2-VAPB. In the control cells 
expressing GFP-APEX2, much lower levels of 
ACBD5 and OSBPL9 were detected (compare 
lanes 7 and 8). This result shows that the 
APEX-method is suited for the identification 
of interaction/proximity partners of VAPB at 
the level of the ER. We noted, however, that 
the difference between specific and unspecific 
biotinylation (i.e. modification in cells 
expressing APEX2-VAPB versus cells 
expressing GFP-APEX2) varied a lot, possibly 
resulting from different transfection 
efficiencies. We therefore modified our 
approach in a way that should allow a better 
control over specific versus unspecific 
biotinylation and combined APEX2-dependent 
biotinylation with the protocol for rapamycin-
dependent targeting of proteins to a protein of 
interest (27). For a first proof-of-principle, we 
constructed a GFP-linked version of APEX2 
with the rapamycin-interaction cassette 
FKBP12 (Fig. 2A, right). Cells were 
transfected with this construct, together with a 
construct coding for mCherry-FRB-VAPB. 
Transfected cells were treated with or without 
rapamycin and subjected to the biotinylation 
protocol. Fig. 2B shows the localization of 
mCherry-FRB-VAPB at the ER and the 
nuclear envelope and the recruitment of GFP-
FKBP12-APEX2 to these sites upon addition 
of rapamycin. This treatment resulted in a 
pronounced overlap of the GFP- and the 
mCherry-signals, suggesting a tight interaction 
of FKBP12-GFP-APEX2 with mCherry-FRB-
VAPB (compare Fig. 1C). As for the “classic” 
approach, cells were then subjected to the 
biotinylation protocol and biotinylated proteins 
were analyzed by Western-blotting. As shown 
in Fig. 2C, ACBD5 and OSBPL9 were 
detected as biotinylated proteins (i.e. in the 
bound fraction) when cells had been treated 
with the drug, indicating rapamycin-dependent 
targeting of APEX2 to mCherry-FRB-VAPB 
and biotinylation of the known VAPB-
interaction partners. The levels of proteins that 
were recovered from the neutravidin beads 
were as high or higher than those found in the 
“classic” experiment using APEX2-VAPB as a 
fusion protein (compare lanes 4 and 8; 
compare also Fig. 3C). The added advantage of 
rapamycin-dependent targeting of APEX2 to 
our protein of interest, however, is twofold: 
first, a simple, single-parameter-change 
experiment (+/- rapamycin) can be performed 
for subsequent analysis of biotinylated proteins 
by quantitative mass spectrometry and 
discrimination between specific and unspecific 
hits. Second, the physical separation of 
APEX2 from the protein of interest allows an 
independent subcellular localization of the 
enzyme and, hence, a control over the 
population of cellular proteins that are 
potential targets for biotinylation. This is of 
particular importance for proteins like VAPB 
that can engage in interactions with different 
sets of proteins residing at distinct 
localizations. 
 
Rapamycin- and APEX-dependent 
identification of proteins by SILAC (RAPIDS) 
Based on the results described above, we 
decided to use the combined 
APEX2/rapamycin system for the 
identification of novel VAPB-proximity 
partners. The outline for an experiment with a 
version of APEX2 with the rapamycin-
interaction cassette and identification of 
proteins by SILAC and quantitative mass-
spectrometry is depicted in Fig. 3A. Briefly, 
cells are grown in media containing either light 
or heavy isotopes of the amino acids lysine and 
arginine and transfected with plasmids coding 
for mCherry-FRB-VAPB and FKBP12-GFP-
APEX2. The two types of cells (“light” and 
“heavy”) are then treated with or without 
rapamycin and subjected to the biotinylation 
procedure. Cellular lysates are combined and 
biotinylated proteins are enriched by binding 
to neutravidin beads. Mass-spectrometry of 
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eluted proteins then allows a direct comparison 
between plus- (i.e. specific biotinylation close 
to mCherry-FRB-VAPB) and minus- (i.e. 
background biotinylation) rapamycin 
conditions. A quantitative evaluation of heavy 
and light tryptic fragments of biotinylated 
proteins should immediately yield proteins that 
were in close proximity to mCherry-FRB-
VAPB in the presence of rapamycin. Fig. S2A 
shows the controls for H2O2-dependent protein 
biotinylation. Prominent bands that are seen in 
the absence of H2O2 correspond to 
endogenously biotinylated proteins. Similar 
transfection efficiencies in the two sets of cells 
(“light” and “heavy”) are controlled in Fig. 
S2B.  
Fig. 3B shows the combined results of two 
independent experiments, each with forward 
(i.e. using light and heavy medium for the 
plus- and minus-rapamycin conditions) and 
reverse reactions (i.e. with changed conditions, 
as depicted in Fig. 3A). Proteins that are 
preferentially biotinylated in the presence of 
rapamycin in both forward- (X-axis) and 
reverse-reactions (Y-axis) are expected in the 
upper left quadrant of the plot. One prominent 
protein here is VAPB itself, indicating its 
modification by the APEX2-fusion protein. 
Many previously known cytoplasmic 
interaction partners of VAPB were also 
identified with high levels of significance, 
including PTPIP51 (RMDN3), YIF1A, 
WDR44, OSBPL9, OSBPL8 and ACBD5. 
GAPDH, by contrast, was found in the cloud 
of proteins that were hardly affected by 
rapamycin, close to the intersection of the x- 
and the y-axis. The list of identified proteins is 
presented in Table S1. Interestingly, the INM-
protein emerin was also identified with a high 
significance. Another potential interaction 
partner is TMEM43, also known as LUMA, a 
membrane protein that interacts with emerin at 
the INM (36) and plays a role in certain forms 
of muscular dystrophies (37). Its localization 
is, however, controversial, since it was mainly 
found in zonula adhaerens and punctum 
adhaerens plaques in another study (38). 
Another nuclear protein that was identified is 
the AT-rich interactive domain-containing 
protein 4 A (ARID4A). This protein, also 
known as Rbbp1, is a retinoblastoma-binding 
protein (39) with functions in chromatin 
remodeling (40). The significance of the 
proximity and/or interaction of VAPB and 
ARID4A remains to be investigated.  
Next, we performed Western-blotting to 
confirm the mass-spectrometry data. As shown 
in Fig. 3C, high levels of mCherry-FRB-
VAPB, ACBD5, OSBPL9 and emerin were 
detected in the bound fraction when the cells 
had been treated with rapamycin, confirming 
rapamycin-dependent biotinylation. For 
GAPDH, by contrast, very similar levels were 
observed for rapamycin-treated and non-
treated cells. Based on the successful 
identification of known interaction partners, 
we termed our approach “RAPID-SILAC” or 
“RAPIDS” (Rapamycin- and APEX-dependent 
identification of proteins by SILAC). 
 
RAPIDS using a nuclear version of APEX2 
The identification of emerin supported the 
notion that VAPB can reach the INM (compare 
Fig. 1), although emerin could also localize to 
other regions of the cell (41,42). Two 
parameters of the assay as performed above 
disfavor the identification of bona fide INM-
proteins: first, FKBP12-GFP-APEX2 is found 
all over the cell and may preferentially interact 
with VAPB that localizes to the ER upon 
addition of rapamycin. Second, the version of 
VAPB in this experiment contains a large 
cytoplasmic mCherry-tag. Although the 
protein can reach the INM to some extent (Fig. 
1C), the efficiency of diffusion of proteins 
from the ER via the outer nuclear membrane to 
the INM in general is clearly affected by the 
size of the cytoplasmic domain (43-47). We 
therefore modified our approach twofold (Fig. 
4A). First, we used a version of APEX2, 
APEX2-dGFP-NLS-FKBP12, which strongly 
accumulates in the nucleus of transfected cells 
as a result of its nuclear localization signal. 
Hence, biotinylation of nuclear proteins or 
INM-proteins should be favored. Second, we 
designed a smaller version of VAPB, HA-
FRB-VAPB, which we expect to diffuse more 
readily across the nuclear pore to the INM than 
the mCherry-tagged version. As shown in Fig. 
4B, APEX2-dGFP-NLS-FKBP12 localized 
largely in the nucleus in the absence of 
rapamycin. Upon addition of the drug, the 
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reporter protein was sequestered to the nuclear 
envelope, suggesting binding to HA-FRB-
VAPB at the INM. We then performed 
RAPIDS and could show that VAPB (i.e. HA-
FRB-VAPB in this experiment) was 
prominently biotinylated in the presence of 
rapamycin (Fig. 4C, D). By quantitative 
proteomics, we identified at least 22 
biotinylated proteins that were enriched on the 
neutravidin beads upon addition of rapamycin 
to the cells, suggesting their close proximity to 
HA-FRB-VAPB (Fig. 4C and Table S2). 
Strikingly, many of the proteins identified are 
known to reside on the nuclear side of the 
nuclear envelope. The proximity-candidates 
fall into three categories: first, proteins of the 
INM like emerin, the lamina-associated 
polypeptide 1 (LAP1 or TOR1AIP1, Torsin-
1A-interacting protein 1; (48)) and LAP2b 
(TMPO, thymopoetin; (48,49)). Another 
protein in this category is TMEM43, which we 
also found with mCherry-FRB-VAPB as a bait 
(Fig. 3); second, proteins of the nuclear pore 
complex (NPC) like Nup153 (50), Tpr (51) 
and ELYS (AHCTF1; (52)) and third, 
components of the nuclear lamina like lamin A 
and lamin B (LMNA, LMNB; (53)). To 
confirm preferential biotinylation of candidates 
in the presence of rapamycin, we performed 
Western-blotting of proteins eluted from the 
neutravidin beads (Fig. 4D). Essentially all the 
tested protein showed increased recovery from 
neutravidin beads upon treatment of cells with 
rapamycin, including ELYS, lamin A/C, LAP1 
(TOR1AIP1), LAP2b (TMPO) and emerin. 
Together, our results show that RAPIDS 
allows the identification of known interaction 
partners of VAPB and, possibly, of novel 
proximity- and/or interaction partners.  
 
Validation 
Proteins identified by RAPIDS could be direct 
or indirect binding partners of VAPB and 
occur in biochemically stable complexes or 
just reside in very close proximity to our 
protein of interest. As a first step to distinguish 
between these possibilities, we performed co-
immunoprecipitation experiments, combined 
with a crosslinking approach to stabilize low-
affinity interactions. First, we 
immunoprecipitated endogenous VAPB using 
a specific antibody and analyzed the 
precipitate for co-precipitating proteins. As a 
control, total IgG was used (Fig. 5A). For the 
established binding partners of VAPB, 
ACBD5 and OSBPL9, and also for emerin and 
TMEM43, specific co-precipitation with 
VAPB was observed when the cells had been 
treated with the cleavable bi-functional 
crosslinker dithiobis(succinimidyl propionate) 
(DSP). For OSBPL9 and TMEM43, co-
precipitation above the IgG-background was 
also seen in the absence of the crosslinker, 
suggesting tight interactions. To corroborate 
these findings, we also used HA-FRB-VAPB-
overexpressing cells for co-
immunoprecipitation experiments, again with 
and without DSP as a crosslinking reagent. As 
shown in Fig. 5B, low levels of ACBD5 and 
OSBPL9 co-precipitated with overexpressed 
HA-FRB-VAPB. The levels of coprecipitated 
proteins strongly increased when the cells had 
been treated with DSP prior to cell lysis 
(compare lanes 5 and 7). For emerin and 
TMEM43 and, to some extent, for ELYS, co-
precipitation was observed in the cross-linked 
samples, suggesting that the corresponding 
complexes exist in intact cells. Very low levels 
of co-precipitating proteins were observed 
when the cells had been transfected with a 
plasmid coding for HA-FRB (lanes 6 and 8). 
Together, these results show that VAPB indeed 
interacts with some of the proteins that were 
identified as proximity partners by RAPIDS. It 
remains to be investigated whether these 
interactions are direct or indirect. 
Next, we performed proximity ligation assays 
(PLAs, (54)), which detect interactions (or at 
least proximity) of endogenous proteins and 
allow statements about the precise localization 
of the protein-protein interactions. These 
assays are based on the decoration of proteins 
in fixed cells, first with specific primary 
antibodies and subsequently with 
oligonucleotide-linked secondary antibodies. If 
the proteins of interest are in close proximity 
(i.e. within ~40 nm), subsequent ligation and 
amplification reactions lead to formation of a 
fluorescent product that can easily be detected 
by microscopy. We first analyzed VAPB with 
respect to its interaction with known binding 
partners that were also detected by RAPIDS, 
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namely ACBD5 and OSBPL9. To characterize 
our antibodies, we performed 
immunofluorescence analysis. As shown in 
Fig. S3A and B, ACBD5 co-localized with the 
peroxisomal marker protein PMP70, and 
OSBPL9 with the Golgi-marker GM130, 
indicating the specificity of the ACBD5- and 
the OSBPL9-antibodies. In PLAs, specific 
interactions of VAPB were observed with 
characteristic patterns of dots: for ACBD5 
(Figs. S3C, D), dots were found scattered all 
over the cell, consistent with signals derived 
from ER-peroxisome interactions. For 
OSBPL9, the observed dots were largely found 
in an area corresponding to the Golgi 
compartment (Figs. S3E, F). The specificity of 
the signals was supported by single-antibody 
controls. These results show that our 
antibodies are suitable for a faithful detection 
of VAPB-protein interactions. Next, we 
performed PLAs with antibodies against 
VAPB and emerin or ELYS (Fig. 6). TMEM43 
was not analyzed here due to lack of PLA-
suitable antibodies. For emerin, PLA-dots were 
mostly observed at the nuclear rim, consistent 
with the major localization of emerin at the 
INM (Fig. 6A). For ELYS (Fig. 6B), PLA-dots 
were observed at the nuclear envelope, but also 
in the nuclear interior. For both proteins, the 
number of dots decreased significantly when 
VAPB had been depleted by specific siRNAs 
as well as in single-antibody-controls, 
demonstrating the specificity of the PLA. In 
summary, co-immunoprecipitation 
experiments and PLA-assays suggest that 
VAPB indeed forms complexes with proteins 
of the INM and/or the NPC. Figure 7 depicts 
the interactome of VAPB, as revealed by our 





The known binding partners of VAPB localize 
exclusively to the cytoplasm or to cytoplasmic 
membranes. The INM-localization of VAPB 
therefore prompted us to search for nuclear 
proteins that could interact with VAPB or are 
at least in close proximity to VAPB at the level 
of the INM or the NPC. For this, affinity-based 
methods that require an initial cell-lysis step 
were not very promising, since the lysis 
buffers must fulfill two conflicting criteria: 
they must be strong enough to solubilize 
protein complexes like the nuclear lamina or 
the NPC, yet maintain the interactions of 
interest. Indeed, validation of our candidate 
proteins by co-immunoprecipitation 
approaches required a careful choice of 
specific reaction conditions concerning the 
lysis buffer, the specific antibody and, 
importantly, the crosslinker used for 
stabilization of protein-protein interactions. As 
an alternative, proximity-based approaches like 
BioID and the APEX-system have the 
advantage of targeting proteins in their natural 
environment, the living cells. BioID, in fact, 
was initially developed to probe the nuclear 
lamina for interaction partners of lamin A (18). 
In the last couple of years, APEX-based 
biotinylation approaches have been used very 
successfully for the analysis of the interactome 
of many proteins (9,20-23,25,31-35). With 
RAPIDS, we now introduce a method that 
combines APEX2-dependent biotinylation, 
rapamycin-dependent targeting of the enzyme 
to proteins of interest, and quantitative 
proteomics using SILAC. The use of 
rapamycin to induce rapid targeting of APEX2 
to a specific subcellular localization should 
facilitate the discrimination between proteins 
that are modified in a specific vs. a nonspecific 
manner. Furthermore, a careful choice of the 
tags used for APEX2- (here: +/- NLS) and the 
protein of interest (here: HA vs. mCherry) may 
strongly affect the spectrum of identified 
proteins. This is of particular importance for 
proteins of the INM, where the size and the 
nature of the tag may affect efficient targeting 
of proteins to their final destination. In general, 
the approach to physically separate the 
APEX2-enzyme from the protein of interest 
offers a tight control over the cellular proteins 
that are potential targets for biotinylation. This 
is a clear advantage for proteins like VAPB 
that can engage in interactions at different 
intracellular contact sites. Notably, a similar 
targeting approach using the rapamycin 
analogue AP21967 as a dimerizing agent was 
very recently described (55). In 2C-BioID, the 
authors used the rapamycin analogue AP21967 
to initiate dimerization of a biotin-protein 
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ligase and a protein of interest to analyze the 
interactomes of LAP2β and lamins A and C as 
a proof of principle.  
The feasibility of RAPIDS was demonstrated 
by the identification of many of the previously 
known binding partners of VAPB (Fig. 3). 
Furthermore, we identified several novel 
nuclear proximity partners of VAPB, 
consistent with the INM-localization of the 
protein. For this, usage of our nuclear version 
of APEX2 was important, as it favors the 
biotinylation of nuclear proteins. Fig. 7 
summarizes our findings and also indicates 
some of the proteins that had previously been 
identified as binding partners of VAPB. 
Together, RAPIDS is a versatile method for 
the identification of proteins that are in close 
proximity to a protein of interest. This 
modification of the classic APEX-approach 
should be applicable to proteins residing at 
different subcellular localizations.  
 
VAPB at the INM 
To our knowledge, a nuclear localization of 
VAPB itself has not been documented so far, 
except in a very recent publication (30). Using 
our rapamycin-dependent dimerization assay 
as well as immunoelectron microscopy, we 
now unequivocally show that VAPB can 
indeed reach the INM and can also be detected 
in close proximity to NPCs (Fig. 1). At this 
point, we cannot say with certainty, which 
percentage of the entire cellular pool of 
endogenous VAPB resides at the INM. In 
immunofluorescence, the ratio of the nuclear 
envelope- and the ER-signal of VAPB is 
affected by the buffer conditions (Fig. 1A). In 
immunoelectron microscopy (Fig. 1D), epitope 
masking is a general issue and could affect 
nuclear and cytoplasmic immunoreactivity of 
VAPB differently. Hence, other, more 
quantitative methods are required for an 
accurate determination of VAPB-levels at 
different localizations within the cell. 
VAPB has been described as a protein that 
localizes to ER-contact sites (2). Using 
RAPIDS under conditions that should favor 
the identification of cytoplasmic 
binding/proximity partners (i.e. with mCherry-
FRB-VAPB and FKBP12-GFP-APEX2; Figs. 
2 and 3), we found many of the previously 
known interaction partners of VAPB, 
including oxysterol binding proteins, PTPIP51 
and ACBD5. Most of the identified proteins 
associate with membranes and many of them 
localize to the ER (see Table S1), consistent 
with the major localization of mCherry-FRB-
VAPB. Nevertheless, we also identified emerin 
as a mainly nuclear protein using this 
approach, in agreement with the observation 
that mCherry-FRB-VAPB can reach the INM 
(Fig. 1C). A different picture emerged when 
we used FRB-VAPB with an HA-tag at the N-
terminal end instead of an mCherry-tag and 
APEX2-dGFP-NLS-FKBP12 as a nuclear 
version of the biotinylating enzyme (Fig. 4 and 
Table S2). Under this condition, we identified 
significantly more nuclear proteins, including 
emerin and other membrane proteins of the 
INM, several nucleoporins and components of 
the nuclear lamina. This result is consistent 
with the observation that the efficiency of 
translocation of proteins from the outer to the 
inner nuclear membrane inversely correlates 
with the size of the cytoplasmic/nuclear region 
of the protein (43-47). Since the HA-tag is 
significantly smaller than the mCherry-tag, a 
larger proportion of the overexpressed protein 
is expected to reach the INM via passive 
diffusion (45), where, upon rapamycin 
treatment, the nuclear version of APEX2 can 
then initiate efficient biotinylation of 
neighboring proteins.  
Importantly, interaction of endogenous VAPB 
or overexpressed VAPB with emerin and 
TMEM43 could be confirmed by co-
immunoprecipitation experiments, where the 
novel binding partners behaved very similar to 
the established binding partners ACBD5 and 
OSBPL9 (Fig. 5). Interestingly, co-
precipitation of TMEM43 with emerin has 
been described previously (36). For 
VAPB/emerin and VAPB/ELYS we also 
confirmed a close proximity in situ, using 
PLA-assays (Fig. 6). For emerin, PLA-dots 
were largely restricted to the nuclear envelope, 
consistent with the predominant localization of 
the protein. ELYS is a nucleoporin that can 
also localize to the nuclear interior in 
interphase cells (52) and plays a role in early 
steps of post-mitotic NPC-assembly (56,57). 
Hence, a role of VAPB in this process could be 
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envisaged. ELYS has previously been 
suggested to interact directly with VAPB 
based on an FFAT-like motif in its sequence 
(2,10). In our PLAs, we also observed 
intranuclear dots, suggesting that not only 
ELYS, but also VAPB might reside in the 
nucleoplasm. This seems counterintuitive, 
since VAPB is a membrane protein. Being a 
tail-anchored protein, however, a soluble pool 
of it must exist and a fraction could even reach 
the nuclear interior. At this point, we can only 
speculate about the functional significance of 
INM-localization of VAPB. VAPB has been 
implicated in the transport of emerin and 
nucleoporins to the INM and the NPC, 
respectively (15). 
In summary, our findings suggest that the 
interaction repertoire of VAPB is even larger 
than previously thought. VAPB not only serves 
as a bridging factor at multiple contact sites of 
the ER with mitochondria, peroxisomes, the 
Golgi apparatus and the plasma membrane, but 
also localizes to the INM, where it may contact 
several nucleoporins, integral membrane 





Standard procedures were used for cloning and 
the obtained constructs were confirmed by 
sequencing. To obtain pcDNA3-FKBP12-
GFP-APEX2, the FKBP12 coding sequence 
was originally derived from pcDNA3-FKBP12 
(27,58) using primers G1562 and G1563 and 
cloned into pcDNA3-Connexin43-GFP-
APEX2 (Addgene plasmid #49385) through 
AflII and BamHI, thereby replacing the 
Connexin43 coding sequence (oligonucleotides 
are listed in Table S3). For APEX2-dGFP-
NLS-FKBP12, the APEX2 coding sequence 
was amplified by PCR using pcDNA3-
Connexin43-GFP-APEX2 as a template and 
primers G1573 and G1571. The PCR product 
was cloned into a pEGFP-C1 derivative 
encoding dGFP-cNLS-FKBP12 through BcuI. 
For pmCherry-FRB-VAPB, the VAPB coding 
sequence was amplified by PCR using primers 
G1390 and G1386 and pCAN-myc-VAPB (59) 
as a template. The PCR product was cloned 
into a pmCherry-C1 derivative coding for 
mCherry-FRB through KpnI and BamHI.  
For pEF-HA-FRB-VAPB, the FRB coding 
sequence (as above) from mCherry-FRB was 
first inserted into a modified pEF-HA vector 
(60) via NcoI and EcoRI, generating pEF-HA-
FRB. The VAPB coding sequence was 
amplified by PCR using primers G1512 and 
G1511 and pCAN-myc-VAPB (59) as a 
template. The PCR product was then inserted 
into pEF-HA-FRB plasmid through EcoRI and 
SpeI. To obtain pEGFP-APEX2, APEX2 was 
amplified from pcDNA3-FKBP12-GFP-
APEX2 using primers G1854 and G1855 and 
cloned into pEGFP-C1 through EcoR1 and 
BamH1. For APEX2-VAPB, VAPB was 
amplified from pmCherry-FRB-VAPB using 
primers G1512 and G1386 and cloned via 
EcoR1 and BamH1 into pAPEX2-C1, which 
had been generated by exchanging the 
mCherry sequence of pmCherry-C1 for that of 
APEX2. 
 
Cell culture and transfection 
HeLa P4 cells (61) were obtained from the 
NIH AIDS Reagent Program. Cells were 
cultivated in DMEM (Life technologies, 
Carlsbad, CA, USA) supplemented with 10% 
(v/v) FBS (Life technologies, Carlsbad, CA, 
USA), 100 U ml-1 penicillin, 100 µg ml-1 
streptomycin and 2 mM L-glutamine (Life 
technologies, Carlsbad, CA, USA) under 5% 
CO2 at 37°C. They were tested regularly for 
contamination by mycoplasma. 
For SILAC, cells were grown in medium 
containing heavy or light isotopes of arginine 
and lysine. For this purpose, DMEM (high 
glucose) lacking glutamine, lysine and arginine 
(Thermo Fisher Scientific, Waltham, MA, 
USA) was supplemented with 10% (v/v) 
dialyzed FBS (Life technologies, Carlsbad, 
CA, USA), 6 mM L-glutamine (Life 
technologies), 100 U ml-1 penicillin and 100 
µg ml-1 streptomycin. To obtain SILAC media 
with heavy and light isotopes, either 0.4 mM 
13C615N2-L-lysine (Silantes, Munich, Germany) 
and 0.2 mM 13C615N4-L-arginine (Silantes, 
Munich, Germany) or 0.4 mM 12C614N2-L-
lysine (Sigma-Aldrich, St. Louis, MO, USA) 
and 0.2 mM 12C614N4-L-arginine (Sigma-
Aldrich, St. Louis, MO, USA) were added, 
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respectively. To ensure sufficient incorporation 
of heavy amino acids, cells were passaged five 
to seven times in SILAC medium before the 
biotinylation experiment, and the incorporation 
rate was confirmed to be ≥97% by mass 
spectrometry. 
Transfections were performed according to the 
calcium phosphate method (62). Briefly, the 
respective plasmids were mixed with 250 mM 
CaCl2. After the addition of the same amount 
of HEPES buffer (50 mM HEPES, pH 6.98, 
250 mM NaCl, 1.5 mM NaHPO4) and 20 min 
incubation at room temperature, the mixture 
was added to the cells, which were then grown 
as above. 
siRNA mediated knockdown of VAPB was 
carried out using Lipofectamine RNAiMAX 
(Thermo Fisher Scientific, Waltham, MA, 
USA) following the protocol of the 
manufacturer. VAPB siRNA 
(GCUCUUGGCUCUGGUGGUUUU, 
AAAACCACCAGAGCCAAGAGC; Sigma), 
and ON-Target plus non-targeting siRNA 
(Dharmacon, Lafayette, CO, USA, D-001810-
01-50) were used at a final concentration of 
100 nM. 
 
Rapamycin-dependent biotinylation assay 
HeLa P4 cells were grown in 10 cm dishes in 
SILAC medium as described above. Two sets 
of cells (in “light” or “heavy” medium) were 
transfected with pmCherry-FRB-VAPB and 
pcDNA3-FKBP12-GFP-APEX2 or pEF-HA-
FRB-VAPB and pAPEX2-dGFP-NLS-
FKBP12, using the same transfection mix to 
ensure similar expression levels, and grown to 
confluency. Cells were then incubated for 30 
min with 500 µM biotin-phenol (Iris Biotech, 
Marktredwitz, Germany), with or without 200 
nM rapamycin (Sigma Aldrich, St. Louis, MO, 
USA). For each experiment, forward and 
reverse reactions were performed. For forward 
reactions, cells grown in “light’’ SILAC 
medium were treated with rapamycin and cells 
grown in “heavy” SILAC medium were not. 
For reverse reactions, this labeling scheme was 
switched. After incubation with biotin-phenol 
and rapamycin, 1 mM H2O2 was added at room 
temperature. After 1 min, the medium was 
aspirated and cells were washed twice with 
quenching buffer (5 mM Trolox, 10 mM NaN3, 
10 mM sodium ascorbate in PBS) and once 
with PBS. Cells used for fluorescence 
microscopy were fixed immediately.  
For Western blot and SILAC analyses, cells 
from each dish were lysed with 1 ml RIPA 
buffer (50 mM Tris, pH 7.4, 5 mM Trolox, 
0.5% (w/v) sodium deoxycholate, 150 mM 
NaCl, 0.1% (w/v) sodium dodecyl sulfate 
(SDS), 1% (v/v) Triton X-100, 1 mM 
phenylmethane sulfonyl fluoride (PMSF), 10 
mM NaN3, 10 mM sodium ascorbate, 1 µg ml-1 
aprotinin, 1 µg ml-1 leupeptin and 1 µg ml-1 
pepstatin). The cell lysate was incubated for 5 
min on ice and centrifuged for 10 min at 
16,000 g and 4°C. The cleared cell lysate was 
used to enrich biotinylated proteins with 
neutravidin beads (Thermo Fisher Scientific, 
Waltham, MA, USA). For mass spectrometry, 
cell lysates derived from three 10 cm dishes 
were pooled, the protein concentration of the 
cell lysates was determined using the Pierce 
660 nm Protein Assay (Thermo Fisher 
Scientific, Waltham, MA, USA) and equal 
protein amounts of samples treated with or 
without rapamycin were mixed prior to 
addition to neutravidin beads. For Western blot 
analyses, the samples were kept separately. For 
each forward or reverse experiment, six 
batches of 130 µl neutravidin beads were 
incubated with 1ml cell lysate overnight at 4°C 
on a rotor. The beads were washed once with 
washing buffer 1 (50 mM HEPES (pH 7.4), 
0.1% (w/v) sodium deoxycholate, 1% (v/v) 
Triton X-100, 500 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), once 
with washing buffer 2 (50 mM Tris (pH 8.0), 
250 mM LiCl, 0.5% (v/v) Nonidet P-40, 0.5% 
(w/v) sodium deoxycholate, 1 mM EDTA) and 
twice with washing buffer 3 (50 mM Tris (pH 
7.4) and 50 mM NaCl). For each washing step, 
the beads were incubated for 8 min at 4°C on a 
rotor. After the last washing step, the buffer 
was removed and bound proteins were eluted 
from the beads by incubation for 5 min at 95°C 
with 90 µl SDS sample buffer (4% (w/v) SDS, 
125 mM Tris pH 6.8, 10% (v/v) glycerol, 
0.02% (v/v) bromophenol blue, 10% (v/v) β-
mercaptoethanol) supplemented with 5 mM 
desthiobiotin (Sigma-Aldrich, St. Louis, MO, 
USA). To increase the protein concentration, 
 at M











Binding partners of VAPB at the inner nuclear membrane 
 
-11- 
three batches of beads were consecutively 
eluted in the same buffer. 
 
Mass spectrometric analyses 
Samples were separated on 4-12% NuPAGE 
Novex Bis-Tris Minigels (Invitrogen, 
Carlsbad, California). Gels were stained with 
Coomassie Blue, and each lane sliced into 11-
12 equidistant bands. After washing, gel slices 
were reduced with dithiothreitol (DTT), 
alkylated with 2-iodoacetamide and digested 
with trypsin (sequencing grade, Promega, 
Madison Wisconsin) overnight. The resulting 
peptide mixtures were then extracted, dried in 
a SpeedVac, reconstituted in 2% 
acetonitrile/0.1% formic acid/ (v/v) and 
analyzed by nanoLC-MS/MS on a hybrid 
quadrupole/orbitrap mass spectrometer (Q 
Exactive, Thermo Fisher Scientific, Dreieich, 
Germany) as described previously (63). Raw 
data were processed using MaxQuant Software 
version 1.5.7.4 (Max Planck Institute for 
Biochemistry, Martinsried, Germany). Proteins 
were identified against the human reference 
proteome (v2017.02, 92.927 protein entries) 
along with a set of common lab contaminants. 
The search was performed with trypsine 
(excluding proline-proximal cleavage sites) as 
enzyme and iodoacetamide as cysteine 
blocking agent. Up to two missed tryptic 
cleavages were allowed for, as well as 
methionine oxidation and protein N-terminal 
acetylation variable modifications. Instrument 
type ‘Orbitrap’ was selected to adjust for MS 
acquisition specifics. Following an initial 
internal recalibration, this translated into an 
MS mass tolerance of 4.5 ppm and an MS/MS 
mass tolerance of 20 ppm. Protein and peptide 
results lists were thresholded at False 
Discovery Rates (FDR) of 0.01, using a 
forward-and-reverse decoy database approach. 
The Arginine R10 and Lysine K8 labels 
including the ‘Re-quantify’ option were 
specified for relative protein quantitation. 
Perseus Software version 1.5.6.0 (Max Planck 
Institute for Biochemistry, Martinsried, 
Germany) was used for statistical evaluation of 
relative protein quantitation values from the 
MaxQuant Software results and a two-sided 
Significance B test (64) was performed using 
normalized log2 ratios. For the analysis, a 
Benjamini-Hochberg correction was applied 
and a threshold value of 0.05 was chosen. 
Mass spectrometry experiments were 
performed twice, each with two biological and 
two technical replicates. 
 
Data availability 
The MS proteomics data have been deposited 
to the ProteomeXchange Consortium via the 
PRIDE (65) partner repository with the dataset 




Western blot analyses 
Western blotting was performed according to 
standard methods using HRP-coupled 
secondary antibodies. To detect biotinylated 
proteins, they were separated by SDS-PAGE 
using 4-12% NuPAGE Novex Bis-Tris 
Minigels (Invitrogen, Carlsbad, California). 
After transfer to nitrocellulose, the membranes 
were incubated in blocking buffer (3% BSA in 
TBS-T (24.8 mM Tris, pH 7.4, 137 mM NaCl, 
2.7 mM KCl, 1% (v/v) Tween 20)) overnight 
at 4°C. Incubation with streptavidin-HRP 
(Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA; diluted 1:5,000-1:40,000 in 
blocking buffer) for 1 h at room temperature 
was followed by three washing steps with 
TBS-T. For detection of proteins, Immobilon 
Western Chemiluminescent HRP Substrate 
(Millipore, Burlington, MA, USA) and a 
luminescent image analyzer (LAS-3000; Fuji, 
Tokyo, Japan) were used. Signal intensities 
were measured using Image Studio Lite (Ver. 
5.2). Two-way analysis of variance (ANOVA) 
followed by Bonferroni post-test was used for 
statistical analysis and a confidence interval of 
95% was set. Primary and secondary 
antibodies are listed in Table S4.  
 
Immunofluorescence and microscopy 
For fluorescence microscopy, cells were grown 
on coverslips and fixed with 4% (v/v) para 
formaldehyde. Cells expressing fluorescently 
labeled proteins were mounted directly with 
MOWIOL supplemented with 1 µg/ml DAPI. 
For immunofluorescence, fixed cells were 
permeabilized with 0.5% (v/v) Triton X-100 in 
PBS for 5 min at room temperature and 
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blocked with 3% (w/v) BSA in PBS for 20 min 
at room temperature. Staining was performed 
for 1 h at room temperature using appropriate 
primary antibodies and fluorescently labeled 
secondary antibodies (Table S4), which were 
diluted in 3% BSA in PBS. Afterwards, cells 
were embedded in MOWIOL-DAPI. 
Microscopic analysis was performed using an 
LSM510 Confocal laser scanning microscope 




For immunoelectron microscopy, HeLa cells 
were fixed with 2% paraformaldehyde, 0.2% 
glutaraldehyde in PHEM buffer (60 mM Pipes, 
25 mM Hepes, 2 mM MgCl2, 10 mM EGTA, 
pH 6.9) for 1 h, washed with PHEM, and 
scraped off. Cells were pelleted (200 x g, 2 
min) and resuspended in 0.1% glycine in PBS, 
pelleted (400 x g, 2 min), resuspended in 0.1% 
glycine in PBS (15 min), pelleted (400 x g, 2 
min), resuspended in 1% gelatin (Dr. Oetker) 
at 37°C for 10 min, pelleted (400 x g, 2 min), 
resuspended in 10% gelatin for 10 min at 
37°C, then replaced on ice. Pellets were 
immersed in 15% PVP (polyvinylpyrrolidone, 
10 kDa, Sigma), 1.7 M sucrose in PBS 
overnight, then mounted and frozen in liquid 
nitrogen and sectioned on a cryo-
ultramicrotome (Leica UC6 with FC6). 
Cryosections were thawed and placed at 37°C, 
washed in 0.1% bovine serum albumin (BSA, 
Sigma) in PBS, then 1% BSA in PBS for 3 
min, followed by overnight incubation with 
undiluted primary antibody (mouse anti-VAPB 
mouse, Proteintech), washed in PBS, incubated 
with 10 nm colloidal gold-anti-mouse antibody 
(BBI solutions). Grids were washed in PBS, 
transferred to 1% glutaraldehyde in PBS (5 
min), washed in H2O, and embedded in 2% 
methyl cellulose containing 0.4% uranyl 
acetate (Agar Scientific). Imaging was done 
using a Hitachi H7600 TEM at 100 kV. 
 
Cross-linking and co-immunoprecipitation 
2x106 Hela P4 cells per 10 cm dish were 
transfected with plasmids coding for HA-FRB-
VAPB or HA-FRB. After 24 hours, the cells 
were washed twice with cold PBS containing 
0.1 mM CaCl2 and 1 mM MgCl2 and incubated 
with DSP (Dithiobis (succinimidyl 
propionate), Thermo Scientific) at a final 
concentration of 1 mM in DMSO for two 
hours on ice. For control reactions, DMSO 
alone was used. DSP was quenched by the 
addition of 20 mM Tris-HCl pH 7.4 for 15 
min. The cells were then washed twice with 
cold PBS and lysed with 1 ml lysis buffer 
(0.5% Na-deoxycholate, 50 mM Tris-HCl pH 
7.4, 150 mM NaCl, 0.25% SDS, 0.5% Triton 
X-100 with complete protease inhibitor 
cocktail (Roche)) for 30 min on ice. To reduce 
viscosity, the lysate was passed through a 
27Gx3/4” needle and then centrifuged at 
15,000g for 20 min at 4°C. For 
immunoprecipitation, 25 µl anti-HA-agarose 
beads (Sigma A2095) were washed with 
washing buffer (10 mM Hepes, 150 mM NaCl, 
1 mM EGTA, 0.1 mM MgCl2, 0.1% Triton X-
100 and complete protease inhibitor cocktail). 
The lysate from 24x106 cells was added to the 
beads and rotated for three hours at 4°C. The 
beads were then washed four times with 
washing buffer and proteins were eluted with 
sample buffer containing 50 mM DTT. For 
immunoprecipitation of endogenous protein 
complexes, 4 µg of rabbit-anti-VAPB, rabbit-
anti-ELYS or IgG as a control were 
immobilized on 40 µl Protein A sepharose 4 
Fast Flow beads (GE Healthcare) for three 
hours and incubated with lysates from 24x106 
cells that had or had not been subjected to 
cross-linking as described above. 
 
Proximity Ligation Assay (PLA) 
HeLa cells were seeded at a density of 40,000 
cells/well in 24-well plates. After 48 hours, 
cells were fixed with 4% paraformaldehyde 
and permeabilized with 0.05% (v/v) Triton X-
100. PLA assays were performed using the 
Duolink In Situ PLA kit (Sigma Aldrich, St. 
Louis, MO, USA, DUO 9200). Cells were 
blocked and incubated with mouse anti-VAPB 
and rabbit anti-emerin, rabbit anti-ELYS, 
rabbit anti-ACBD5 or rabbit anti-OSBPL9, 
respectively (see Table S4 for antibodies). 
After ligation and amplification using the 
corresponding PLA probes, the cells were 
counterstained for VAPB and mounted using 
Duolink mounting medium with DAPI. Images 
were acquired on an LSM510 Confocal laser 
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scanning microscope using a 63X /1.4 oil 
immersion lens. 450 cells over three 
independent experiments were analyzed for 
PLA interaction using CellProfiler 2.2 (66). 
One-way analysis of variance (ANOVA) 
followed by Bonferroni post-test was used for 
statistical analysis and a confidence interval of 
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VAPB localizes to the INM.  
(A) HeLa cells were grown on coverslips and subjected to indirect immunofluorescence using antibodies 
against VAPB. Cells were blocked (i) with 3% BSA or (ii) with Sigma Duolink blocking solution.  
(B) HeLa cells were transfected with plasmids coding for mCherry-FRB-VAPB or HA-FRB-VAPB, as 
indicated.  
(C) HeLa cells were co-transfected with plasmids coding for mCherry-FRB-VAPB and dGFP-GST-cNLS-
FKBP12. After treatment with (+) or without (-) rapamycin, cells were fixed and analyzed by confocal 
microscopy. Scale bar, 10 µm.  
(D) HeLa cells were analysed by immunoelectron microscopy, using antibodies against VAPB. C, 
cytoplasm; M, mitochondria; N, nucleus. The arrows indicate nuclear pore complexes. Scale bar, 100 nm. 
 
Figure 2 
Comparison of the classic and a new APEX-approach.  
(A) Schemes of the “direct fusion (classic) approach” (left) and the “rapamycin (new) approach” (right). 
(B) For the direct fusion and the rapamycin approach, cells were transfected with plasmids coding for 
GFP-APEX2 or APEX2-VAPB and FKBP12-GFP-APEX2 and mCherry-FRB-VAPB, respectively. Cells 
were analyzed directly (left) or upon incubation with or without rapamycin (right). Scale bar, 10 µm. 
(C) Cells were transfected as in B and subjected to the biotinylation protocol. Biotinylated proteins were 
enriched using neutravidin beads and total and bound proteins were analyzed by SDS-PAGE followed by 
Western blotting. Note that GFP-APEX2 (lanes 5 and 7) and APEX2-VAPB (lanes 6 and 8) have very 
similar molecular weights. 
 
Figure 3 
Proximity mapping of mCherry-FRB-VAPB by RAPIDS.  
(A) Experimental workflow. Cells grown in “light” or “heavy” medium are co-transfected with plasmids 
coding for FKBP12-GFP-APEX2 and mCherry-FRB-VAPB, and subjected to APEX2-dependent 
biotinylation in the absence or presence of rapamycin. Note that this labelling scheme reflects the reverse 
reaction. In the forward reaction, “light” and “heavy” media are used for cells treated with or without 
rapamycin, respectively. Proteins from cell lysates are bound to neutravidin beads and the total and the 
bound fractions are analyzed by LC-MS.  
(B) The scatter plot resulting from two independent experiments shows normalized log2-ratios of proteins 
eluted from neutravidin beads in forward (heavy medium (H), without rapamycin; light (L) medium, with 
rapamycin; x-axis) and reverse (heavy medium (H), with rapamycin; light (L) medium, without rapamycin 
y-axis) experiments. The plot focuses on the upper left quadrant, because in the forward reaction, low 
H/L-ratios (i.e. negative log2-values) are expected for specific hits, whereas high ratios are expected in the 
reverse reaction. Known interacting partners of VAPB are underlined. Closed circles: proteins that were 
significant in all experiments; open triangles: proteins that were significant only in forward experiments; 
open squares: proteins that were significant only in reverse experiments. 
(C) Total cell lysates (total) and proteins bound to neutravidin beads (bound) from one of the experiments 
depicted in (B) were analyzed by Western blotting, using antibodies against VAPB, ACBD5, OSBPL9 
and emerin and GAPDH as a loading control. 
 
Figure 4 
RAPIDS using HA-FRB-VAPB.  
(A) Experimental workflow. Cells are grown in “light” or “heavy” medium as indicated, co-transfected 
with plasmids coding for APEX2-dGFP-cNLS-FKBP12 and HA-FRB-VAPB, and subjected to RAPIDS 
as described in Fig. 3A. 
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(B) Transfected cells were treated with or without rapamycin as indicated, fixed and analyzed by 
fluorescence microscopy. Scale bar, 10 µm. 
(C) The scatter plot resulting from two independent experiments shows normalized log2-ratios of proteins 
eluted from neutravidin beads in forward (heavy medium (H), without rapamycin; light (L) medium, with 
rapamycin; x-axis) and reverse (heavy medium (H), with rapamycin; light (L) medium, without rapamycin 
y-axis) experiments. As in Fig. 3, the plot focuses on the upper left quadrant. Closed circles: proteins that 
were significant in all experiments; open triangles: proteins that were significant only in forward 
experiments; open squares: proteins that were significant only in reverse experiments. 
(D) Total cell lysates (total) and proteins bound to neutravidin beads (bound) from experiments depicted 
in (C) were analyzed by Western blotting using antibodies against VAPB, ELYS, Lamin B1, Nup153, 
Lamin A/C, TMPO, TOR1AIP1, SEC22b, emerin and GAPDH as a loading control. 
 
Figure 5 
VAPB forms complexes with emerin, TMEM43 and ELYS.  
(A) HeLa cells were treated with (+) or without (-; DMSO as a control) DSP and endogenous proteins 
from cell lysates were precipitated using rabbit-anti-VAPB and rabbit IgG as a control. *, IgG heavy 
chain. 
(B) HeLa cells were transfected with constructs coding for HA-FRB-VAPB or HA-FRB and subjected to 
crosslinking with (+) or without (-; DMSO as a control) DSP. Proteins from cell-lysates were 
immunoprecipitated using anti-HA antibodies. Note that HA-FRB was expressed and precipitated to 
similar levels as HA-FRB-VAPBB (data not shown). (A, B) Precipitated proteins were analyzed by 
Western blotting, detecting VAPB, ACBD5, OSBPL9, emerin, TMEM43, ELYS, the HA-tag and, for 
control, Na+/K+-ATPase, as indicated.  
 
Figure 6 
VAPB is in close proximity to emerin and ELYS.  
(A, B) Cells were treated with siRNAs against VAPB or non-targeting (nt) siRNAs as indicated and 
subjected to PLAs using antibodies against VAPB (A and B) and emerin (A) or ELYS (B), respectively. 
Indirect immunofluorescence was used to detect VAPB. The graphs show the quantification of PLA-
results from three independent experiments, analyzing a total of 450 cells. The bars indicate mean values 
± SD. Single antibody controls were performed to confirm the specificity of PLA interactions. ***, 
P<0.001. Scale bars, 10 µm.  
 
Figure 7 
The VAPB-interactome. Schematic representation of the protein network identified by RAPIDS using 
HA-FRB-VAPB (HA-VAPB) with APEX2-dGFP-cNLS-FKBP12 (NLS-APEX2) or mCherry-FRB-
VAPB (mCherry-VAPB) with FKBP12-GFP-APEX2 (APEX2). Dotted lines indicate interactions that 
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